

Available online at www.sciencerepository.org

Science Repository



Review Article

Review of Anaesthesia and Analgesia in Patients with COVID-19 in Brazil

*Mônica Santos de Melo*¹, *Júlia Ferreira Nogueira*², *Lucas Vinicius Andrade dos Santos*², *Luis Claudio Bettamio de Sousa*², *Raiane Nascimento Santana*², *Weslly Jonas Severo da Silva*², *Wictor Hugo de Souza Silva*² and *Makson Gleydson Brito de Oliveira*^{2*}

¹Department of Education and Health, Federal University of Sergipe, Lagarto, Sergipe, Brazil

²Department of Medicine, Federal University of Sergipe, Lagarto, Sergipe, Brazil

ARTICLE INFO

Article history:

Received: 11 August, 2020

Accepted: 25 August, 2020

Published: 8 September, 2020

Keywords:

COVID-19

SARS-CoV-2

anaesthetics

analgesics

ABSTRACT

Severe acute respiratory syndrome (COVID-19), produced by SARS-CoV-2, remains a challenge for modern medicine and a global health problem. For every 100 patients with COVID-19, about 20 need hospital care. In addition, some patients will be intubated and others under mechanical ventilation. Therefore, it is necessary to use drugs as a sedative and analgesic purpose, mainly. Thus, this study brings a survey on the drugs that can be used for the management of patients with COVID-19 in cases of intubation and mechanical ventilation in Brazil. In this paper, we will report the classes of anaesthetic and analgesic drugs. Highlighting the clinical indications for use, pharmacological characteristics of each drug in terms of doses, pharmacokinetics, pharmacodynamics and possible side effects and, in addition, peculiarities of drugs related to use in patients with COVID-19, when possible.

© 2020 Makson Gleydson Brito de Oliveira. Hosting by Science Repository.

Introduction

The outbreak caused by the new coronavirus (SARS-CoV-2) started in the wholesale seafood market in Wuhan, China, in December 2019 [1]. The virus responsible for the new severe acute respiratory syndrome, called coronavirus disease 2019 (COVID-19), generated an epidemic and shortly thereafter, on March 11, 2020, the World Health Organization (WHO) updated the status to pandemic. The number of patients with COVID-19 has increased rapidly in many countries worldwide [2].

Scientific reports suggest that among those with COVID-19, up to 20% develop serious illness that requires hospitalization [3-6]. About 10% of critically ill patients will be considered for mechanical ventilation, and some may require emergency intubation [2, 3]. Guan *et al.* estimates that 2.3% of patients need tracheal intubation [7]. The purpose of intubation is to protect the airways, in the estimation of corroborating for potential recovery from the disease [8].

Anecdotal evidence suggests that the requirements for sedation and analgesia seem high in patients on mechanical ventilation with COVID-

19 and that intensive use of sedatives, analgesics and even muscle relaxants is necessary [9]. Thus, this study brings a survey on the anaesthetic and analgesic drugs used in Brazil for the management of patients with COVID-19.

Review

Anaesthetic induction is important in severe cases related to the new coronavirus. Several drugs are used in general, anaesthetic practice, but the new health context requires adequacy and selection of drugs that best suit the clinical condition and the reality of the patient affected by COVID-19. The treatment of patients with COVID-19 in an intensive care unit has caused a significant increase in the prescriptions of sedatives at an international level, generating shortages of this class of drugs in all countries [10, 11].

Among drugs used in sedation, induction and maintenance of anaesthesia in COVID-19 patients, there is propofol [12]. This pharmacokinetics involves an onset of action less than 45 sec, with peak action of 1-2 min and a duration of 10-15 min [13]. It has a protein binding rate of 95%, hepatic metabolism and urinary excretion. Its acts

*Correspondence to: Makson Gleydson Brito de Oliveira, Ph.D., Professor, Medicine Department, Federal University of Sergipe, Av. Governador Marcelo Déda, 13, CEP 49400-000, Lagarto, Sergipe, Brazil; Tel: 557936322080; E-mail: makson_gbo@hotmail.com

depressing central nervous system, increasing the action of GABA, reducing heart rate, cardiac output, ventilation and myocardial [14]. The dose utilized in coronavirus patients is 1.5-2 mg/kg, with myotoxicity being observed due to the longtime of exposure to propofol [15]. Some patients develop critical illness myopathy. In children, the risk of propofol syndrome is increased, with a generalized myotoxicity effect after severe myalgia. Often, a lethal condition involving rhabdomyolysis can occur [12].

Etomidate is another drug indicated for anaesthesia induction and maintenance [14]. Its onset of action is lower than 2 minutes, with a peak action in 3-5 min and duration of 5-15 min. It has a protein binding rate of 76%, hepatic metabolism and urinary excretion [16]. So far, their action is potentiated by GABA_A, causing a reduction of cerebral blood flow and myoclonus, reducing eye pressure, peripheral vascular resistance, tidal volume, and respiration rate, which may cause apnea [14]. The dose used in COVID-19 patients is 20 mg associated with midazolam 5 mg [15].

Another sedative drug and anaesthesia inductor is midazolam. This drug has an onset of action lower than 5 minutes, peak action lower than 1 hour and a duration of 2-4 hours, with faster hepatic oxidation and urinary excretion [14, 17]. Midazolam increases neural inhibition centrally mediated by GABA, which causes sedation, amnesia, delirium, reduced cerebral blood flow, cardiac output, respiratory rate, tidal volume and apnea. It has a muscle relax property [14]. The dose used in COVID-19 patients is 5 mg associated with Etomidate 20 mg [15]. Some severe cases of Neuroleptic Malignant Syndrome were related after midazolam use, showing clinical signs as high fever with creatine kinase level elevated and development tachycardia, tachypnea, altered consciousness, and diaphoresis. Some patients develop delirium [18].

Fentanyl is another drug to induce and maintain anaesthesia. Its onset of action is about 1-2 minutes, with peak action of 3-5 min and duration 0.5-1 h, with a protein binding rate of 80%, hepatic metabolism and urinary excretion [14]. It is an opioid agonist, causing analgesia, drowsiness, reduction of cerebral blood flow, heart rate and blood pressure, urinary retention, constipation, apnea, bronchospasm, muscle stiffness, increased ADH, pruritus, nausea and vomiting [13]. The dose used in COVID-19 patients is 100-150 mcg [15]. High doses (more than 60-120 mcg for a 70 kg patient) of fentanyl for intubation are associated with elevated risk of development of postoperative respiratory complications, as pulmonary edema, atelectasis, pneumonia, respiratory failure or reintubation [19].

Alfentanil is a drug that acts as an opioid receptor agonist, with a rapid onset of action, between 1 and 1.5 minutes, reaching its peak of action between 3 and 5 minutes and having an effective duration of 15 to 30 minutes, for intravenous administration and in doses of 20 to 40 µg/kg for anaesthetic induction and 0.5 to 1.5 µg/kg/min for maintenance in elective procedures [13]. It has a 92% protein binding rate and is metabolized in the liver and excreted in the urine [20]. Its effects are the same as fentanyl. The study by Lovell *et al.* observed the drugs used in patients with COVID-19 in palliative care and found that the dose of alfentanil used in some patients was, on average, 500 µg/24h, ranging between 150 and 1000 µg/24 h [21]. The use of alfentanil in combination with inhaled anaesthetics, can potentiate nausea and vomiting [13, 14].

Sufentanil also acts as an opioid receptor agonist, with the onset of action between 1 and 2 minutes and peak action between 3 and 5 minutes, with an effective duration of 15 to 30 minutes for intravenous administration in doses of 0.5 to 1 µg/kg for anaesthetic induction and 0.3 to 0.6 µg/kg/h for maintenance in elective procedures [13]. Its protein binding rate is 90% and is metabolized in the liver and small intestine and excreted in the urine [22]. Its effects and possible complications are the same as those of fentanyl and alfentanil [13, 14]. Unlike alfentanil, no solid scientific material showing its use in patients with COVID-19 was found.

Remifentanil is another drug that does anaesthetic induction and maintenance and also acts as an opioid receptor agonist [13]. Its onset of action is faster, staying between 30 and 60 seconds with peak action between 3 and 5 minutes for intravenous administration in doses of 0.5 to 2 µg/kg for anaesthetic induction and 0.1 to 0.5 µg/kg/min for maintenance in elective procedures [13]. The protein binding rate is 70%, it is metabolized by non-specific esterases and its pharmacodynamics is the same as that of fentanyl, alfentanil and sufentanil [14]. Because it is an ultra-fast opioid with a short duration of action, it is associated with the rapid development of tolerance. In the case report by Ahmad *et al.*, 4 ng/ml remifentanil and 0.5 µg/ml propofol were used for conscious sedation, and 6 ng/ml remifentanil with 3 µg/mL propofol with 60 mg of rocuronium for anaesthetic induction [23]. In order to reduce the chances of coughing as much as possible during the intubation process, a higher than the recommended dose of remifentanil was used, and the procedure started after the drug reached its maximum effect.

Bevilacqua *et al.* suggest a high dose of remifentanil alone, which is then combined with small doses of midazolam or propofol during the rapid intubation sequence, based on an anaesthetic technique for carotid surgery, in which a venous infusion of remifentanil of 0.2 to 0.3 µg/kg/min until the patient had a profound state of analgesia and sedation, but still reacting to some verbal stimuli and responding to respiratory commands [24]. Tang and Wang responded to the letter from Bevilacqua *et al.* agreeing with the possibility of using remifentanil for intubation in positive COVID-19 patients, but noting that the method is not classified as a rapid sequence of intubation but as a deep induction, in addition to highlighting possible complications such as higher risks of aspiration because it requires more time and hemodynamic risk [24, 25].

Neuromuscular blockers (NMBs) are widely used for surgical anaesthesia, as well as for postoperative and non-surgical analgesia. NMBs offer distinct benefits over general or neuraxial anaesthesia in certain clinical situations [26]. American Society of Regional Anaesthesia, the European Society of Regional Anaesthesia and Pain Medicine and the European Society of Anaesthesiology have published practical recommendations for neuraxial anaesthesia and peripheral nerve block in patients with COVID-19 [27-29]. As with sedatives, neuromuscular blockers had their use drastically increased in the pandemic of COVID-19 in ICUs at the international level, generating shortages in several countries [10, 11].

NMBs are drugs indicated for orotracheal intubation, intraoperative muscle relaxation and better conditions for mechanical ventilation [30]. Cisatracurium presents itself as a NMBs that competitively binds to

cholinergic receptors and antagonizes the action of acetylcholine. It has an onset of action between 1 and 2 minutes, peaking between 3 and 4 minutes and has an average duration of 25 to 44 minutes for intravenous administration at doses of 0.15 to 0.20 µg/kg for induction and 1 to 3 µg/kg/min for maintenance [31]. It has a protein binding rate of 82%, is metabolized by non-specific esterases and via Hofmann, being excreted in the urine and feces [31]. It can cause muscle weakness and apnea, bradycardia and hypotension. Skin flushing, skin rash and bronchospasm are uncommon reactions and are not the NMBs of choice for the rapid sequence of intubation [30, 31]. No solid scientific material evidencing its use in patients with COVID-19 has been found.

Pancuronium acts antagonizing the action of acetylcholine on cholinergic receptors; it starts to act between 3-4 minutes IV and is metabolized primarily by the liver and has renal elimination [32]. As it is the first neuromuscular blocker of the ammonium steroid group discovered, there is no receptor selectivity and it can cause vagal block. Thus, high doses can cause tachycardia and hypertension [33]. There are few information regarding the dose due to its lower use and replacement by the new generations of the drug. Vecuronium is a pancuronium-like drug, with hepatic metabolism and elimination occurring in bile and urine [34]. Its onset of action is 2-3 minutes IV [32]. Because it is a more selective drug, there are fewer occurrences of cardiovascular effects [33]. Administration doses are normally 0.08-0.1 mg/kg IV for induction, 0.25 mg/kg for rapid sequence intubation and 0.05-0.1 mg/kg/h IV in maintenance [31].

Rocuronium is a neuromuscular blocker very similar to vecuronium with the same duration of action, but it starts to act much faster, 1 min IV [18, 34]. It is one of the most used drugs in orotracheal intubations in patients with COVID-19. The usual dose for induction is 0.6-1.2 mg/kg IV and for maintenance is 0.3-0.6 mg/kg/h IV [31]. In the current scenario, the use of a maximum dose of this drug is observed, as in hospital protocols in which the dose of rocuronium used is 1.2 mg/kg in the induction phase [35]. Thus, there may be greater complications with these patients, and anaphylaxis is what most occurs [36]. Another drug belonging to the same class is atracurium, which starts to act in 2-3 minutes IV and is metabolized by non-specific esterases and via Hofmann and has urinary excretion [18]. It can cause vasodilatation due to histamine release and it doesn't have a cumulative effect [33]. It is mainly used in the phase post orotracheal intubation in patients with COVID-19 [35].

Succinylcholine is a neuromuscular muscle blocker that also acts on nicotinic cholinergic receptors antagonizing acetylcholine; it has a rapid onset of action and a rapid duration [37]. The onset of action occurs within 1-2 minutes and is usually used at a dose of 0.5 to 1.5 mg/kg [32]. Despite being an important drug for the installation of an invasive airway, with a good safety margin in these procedures, its prolonged use can induce hypercalcemia, causing arrhythmia or even leading to cardiorespiratory arrest [38]. Despite its risks, succinylcholine is usually available and reliable [39].

Adjuvant drugs are essential to avoid the potentially damaging consequences of physiological responses to airway manipulation during endotracheal intubation. These responses include vagal stimulation bradycardia, severe asthma, high intracranial pressure, exacerbated cardiovascular conditions, as well as the patient in shock [40]. Some

peculiarities are to use lidocaine to reduce the likelihood of bronchospasm when beta-2 agonist therapy has not been administered. In the case of alpha-adrenergic agents, here exemplified by dexmedetomidine, used to increase systemic vascular resistance. Magnesium sulfate has minimal adverse effects at the indicated doses and is widely available and inexpensive [41].

Lidocaine is an amine ethylamide, a local anaesthetic and antiarrhythmic agent widely used for its rapid anaesthetic effect, especially when used parenterally [42]. In addition, studies suggest that this drug has a direct influence on improving the inflammatory response [43]. Special attention should be paid to its prolonged use in patients with liver disease due to their renal excretion and to patients with heart block without the use of a pacemaker, Stoke-Adams syndrome and Wolff-Parkinson-White [44]. Its safety dose for orotracheal intubation is 1 to 1.5 mg/kg in bolus with direct benefits in preventing bronchospasm [39]. Another adjuvant drug is dexmedetomidine, which has an alpha 2 agonist action contributing to sedation, decreasing heart rate, blood pressure and involuntary movements [45]. The onset of action is around 5 minutes, with a peak of action between 20 and 30 minutes [46]. The dose of 0.5 to 1 µg/kg is commonly used, and its transport occurs through binding with plasma proteins and its metabolism is hepatic [46]. Although there are data in the literature that suggest an improvement in hypoxemia in patients with COVID-19, the need for scientific evidence to prove this action cannot be ruled out [47].

Magnesium sulfate is a drug used for analgesia in surgical patients. It begins to act in 1 hour and has its peak of action in less than 30 minutes and the duration of action of 0.5 to 4 hours [48]. Magnesium can block N-methyl-D-aspartate receptor and calcium channel, leading to the central nervous system and breathing depression, somnolence and vasodilatation. When used intraoperatively, it decreases the consumption of anaesthetics and muscle relaxants [49]. Also, it reduces the requirement of opioid 24 hours postoperatively [37]. The dose ranges 30-50 mg/kg followed by 10-15 mg/kg for each hour of surgery [46]. Magnesium has side effects, including reduction of the blood pressure, electrocardiogram alteration, nausea and vomit [49]. Ketamine is a racemic mixture that has analgesic, anaesthetic, anti-inflammatory and antidepressant effect [50]. It starts acting in 30 seconds and reaches the peak of action in 3-5 minutes [42]. Ketamine activates the limbic system, induces dissociative anaesthesia and sedation, intense analgesia with minimal respiratory depression at sedative doses (0.25 to 0.5 mg/kg IV) [51]. Ketamine is recognized as a strong psychedelic drug that provokes dissociative states and psychotic symptoms [50]. Also, it causes hypnosis, delirium, tremors, hallucination and convulsion [42]. Besides that, ketamine exhibits neurotoxicity at high concentrations in animals [50].

An aggravating factor in the pandemic of the new coronavirus is the scarcity in several countries of the main drugs used in anaesthetic induction. Inhaled drugs are being proposed as alternatives in studies, associated with their low cost [52]. Nitrous oxide is an adjuvant, amnesic and analgesic gas used in medicine. It has a fast action in the organism and a partition coefficient of 0.47 [53]. Besides that, it has a minimum alveolar concentration of 104%. Nitrous oxide induces opioidergic neurons in the periaqueductal gray matter and noradrenergic neurons in the locus coeruleus [54]. This gas is used at a 40-70% in oxygen. It

causes disorientation, nauseous, vomit and excitement [42]. Also, it can increase myocardial risk in the perioperative period and is related to neurologic effects in long-term nitrous oxide abuse. Besides that, there are *in vitro* studies that suggest nitrous oxide can have genotoxicity by inhibition of methionine synthase [54].

Isoflurane is widely used and helps maintain general anaesthesia, further reducing the level of consciousness. It is a volatile, non-flammable and poorly metabolized drug (0.2%, with urinary excretion). Its pharmacodynamics is related to inhibition of neurotransmission, an increase of intracranial pressure above 1 MAC (minimum alveolar concentration), headache, excitement in the emergence of anaesthesia, reduction of peripheral vascular resistance, cardiac output and blood pressure and increases heart rate. It also intensifies muscle relaxation, reduces tidal volume and increases respiratory rate [53, 55-58]. It strengthens the effect of NMBs, opioids, nitrous oxide and benzodiazepines. The usual dose is maintained between 0.5 and 1 MAC (0.6-1.2% - expired concentration). This drug is contraindicated in cases of malignant hyperthermia, inhalation induction (irritating to the airways in high concentrations) and procedures that require electrophysiological monitoring [53, 55-58]. Isoflurane offers the highest potency with the lowest dosage requirements for patients in the ICU, it increases heme oxygenase and assists in cytoprotection during cardiac and liver surgeries, and in the long term it helps in the recovery and reduction of bronchospasm from pneumonia by herpes simplex [59, 60].

Sevoflurane, as well as isoflurane, is also widely used, following basically the same indications and pharmacokinetic and pharmacodynamic properties. However, it differs in metabolism, which is hepatic (2-5%) and forms compound A (potentially nephrotoxic) in contact with soda lime. In the dynamic part, it can cause nausea and vomiting. Contraindications and interactions are also quite similar to isoflurane. The usual dose is maintained between 0.5 and 1 MAC (1-2% - expired concentration) [53, 55-58]. Like isoflurane, sevoflurane also increases heme oxygenase and assists in cytoprotection during cardiac and liver surgeries, also helping to improve lung mechanics and gas exchange in a series of cases of babies with severe bronchiolitis and acute respiratory distress syndrome [60]. Nieuwenhuijs-Moeke *et al.* discuss, in their article, a clinical study carried out in animals that shows the superiority of sevoflurane in relation to other anaesthetic drugs in terms of length of stay and mortality and that treatment with sevoflurane improved the partial pressure of oxygen (PaO_2)/ inspired oxygen fraction (FiO_2) and reduced the concentrations of interleukin-6 and $\text{TNF-}\alpha$ in patients treated with sevoflurane [52].

Desflurane is a less used drug compared to other inhalation agents, because it is related to rapid awakening, agitation if there is no adequate analgesia and it requires electronic vaporizer. In general, it has the same pharmacokinetics and pharmacodynamics as isoflurane. Its dose is usually maintained between 0.5 and 1 MAC (3-6% - expired concentration) [53, 55-58]. There is a shortage in the literature of studies that suggest its use for patients affected by COVID-19.

Nieuwenhuijs-Moeke *et al.* conclude that the current situation makes it possible to investigate the potential beneficial effects of volatile anaesthetics on systemic inflammation, sepsis and acute respiratory distress syndrome in mechanically ventilated patients with COVID-19,

while increasing the range of sedative drugs in this population still growing in the ICU [52]. Preclinical data showed that inhaled anaesthetics attenuate lung inflammation and dilate the airways, effects mediated by type A γ -aminobutyric acid (GABA_A) receptors, which are expressed in different types of cells in the lung, promoting a reduction in the production of pro-inflammatory cytokines, while the activation of GABA_A receptors in airway smooth muscle cells stimulates bronchodilation and improves oxygenation [61]. Inhaled sedative regimens have shown modest benefits in faster extubation times after discontinuation of the drug, which is attributable to its exclusive clearance by pulmonary expiration with negligible systemic metabolism [59].

Conclusion

The pandemic scenario causes both rapid technological and scientific advances in order to find solutions to the problems which arise as a result of SARS-CoV-2 and, in accordance with this situation, there should exist an efficient administration of drugs. One of the problems found was the shortage of drugs and the lack of a protocol that gathers all the drugs used in the treatment of COVID-19, introducing details such as the indication of use, pharmacokinetics, pharmacodynamics, doses and side effects. Therefore, we conclude that more in-depth studies on the specific action of each drug and its particularities in a COVID-19 patient should be carried out, aiming to determine possible implementations in its administration.

Author Contributions

All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The authors dedicate this article to all health professionals who are facing COVID-19.

Funding

None.

Conflicts of Interest

None.

REFERENCES

1. Na Zhu, Dingyu Zhang, Wenling Wang, Xingwang Li, Bo Yang et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 382: 727-733. [[Crossref](#)]
2. Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 395: 507-513. [[Crossref](#)]

3. Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395: 497-506. [[Crossref](#)]
4. Xiaobo Yang, Yuan Yu, Jiqian Xu, Huaqing Shu, Jia'an Xia et al. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 8: 475-481. [[Crossref](#)]
5. Barnaby Edward Young, Sean Wei Xiang Ong, Shirin Kalimuddin, Jenny G Low, Seow Yen Tan et al. (2020) Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA* 323: 1488-1494. [[Crossref](#)]
6. Elisabeth Mahase (2020) Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. *BMJ* 368: m1201. [[Crossref](#)]
7. Wei Jie Guan, Zheng Yi Ni, Yu Hu, Wen Hua Liang, Chun Quan Ou et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 382: 1708-1720. [[Crossref](#)]
8. Jolin Wong, Shimin Ong, Lin Stella Ang (2020) Intubation of the patient with a suspected or confirmed COVID-19 infection. *Trends in Anaesthesia & Critical Care* 33: 25-26. [[Crossref](#)]
9. Yichun Jiang, Jun Chen, Fulan Cen, Xu Li, Zhi Song et al. (2020) Importance of respiratory airway management as well as psychological and rehabilitative treatments to COVID-19 patients. *Am J Emerg Med* 38: 1698.e1-1698.e4. [[Crossref](#)]
10. X Pourrat, J F Huon, M Laffon, B Allenet, C Roux Marson (2020) Implementing clinical pharmacy services in France: One of the key points to minimise the effect of the shortage of pharmaceutical products in anaesthesia or intensive care units? *Anaesth Crit Care Pain Med* 39: 367-368. [[Crossref](#)]
11. EAHP (2020) European collaboration to prevent drug shortages.
12. Per Arne Lönnqvist, Max Bell, Torbjörn Karlsson, Lars Wiklund, Anna Stina Höglund et al. (2020) Does prolonged propofol sedation of mechanically ventilated COVID-19 patients contribute to critical illness myopathy? *Br J Anaesth*. [[Crossref](#)]
13. Carneiro AF, Albuquerque MAC, Nunes RR (2016) Bases da anestesia venosa. *Rio de Janeiro: SBA*.
14. García PS, Whalin MK, Sebel PS (2019) Pharmacology of Intravenous Anesthetics. *Pharmacol Physiol Anesth* 193-216.
15. Universidade Federal do Rio de Janeiro (UFRJ) (2020) Protocolos e Fluxos de Trabalho para Anestesiologistas durante a pandemia COVID-19. Hospital Universitário Clementino Fraga Filho.
16. Kotaro Kaneda, Susumu Yamashita, Sukyung Woo, Tae Hyung Han (2011) Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. *J Clin Pharmacol* 51: 482-491. [[Crossref](#)]
17. Ed Horn, Suzanne Amato Nesbit (2004) Pharmacology and pharmacokinetics of sedatives and analgesics. *Gastrointest Endosc Clin N Am* 14: 247-268. [[Crossref](#)]
18. Mitsuhiro Soh, Toru Hifumi, Shutaro Isokawa, Masato Shimizu, Norio Otani et al. (2020) Neuroleptic malignant syndrome in patients with COVID-19. *Am J Emerg Med*. [[Crossref](#)]
19. S Friedrich, D Raub, B J Teja, S E Neves, T Thevathasan et al. (2020) Effects of low-dose intraoperative fentanyl on postoperative respiratory complication rate: a prespecified, retrospective analysis. *Br J Anaesth* 122: e180-e188. [[Crossref](#)]
20. Jörn Lötsch (2005) Pharmacokinetic-pharmacodynamic modeling of opioids. *J Pain Symptom Manag* 29: S90-S103. [[Crossref](#)]
21. Natasha Lovell, Matthew Maddocks, Simon N Etkind, Katie Taylor, Irene Carey et al. (2020) Characteristics, Symptoms Management, and Outcomes of 101 Patients With COVID-19 Referred Hospital Palliative Care. *J Pain Symptom Manage* 60: e77-e81. [[Crossref](#)]
22. Dariusz Maciejewski (2012) Sufentanil in anaesthesiology and intensive therapy. *Anaesthesiol Intensive Ther* 44: 35-41. [[Crossref](#)]
23. I Ahmad, S Wade, A Langdon, H Chamarette, M Walsh et al. (2020) A wake tracheal intubation in a suspected COVID-19 patient with critical air way obstruction. *Anaesth Rep* 8: 28-31. [[Crossref](#)]
24. Sergio Bevilacqua, Vanessa Bottari, Ilaria Galeotti (2020) Systematic Application of Rapid Sequence Intubation With Remifentanyl During COVID-19 Pandemic. *Semin Cardiothorac Vasc Anesth*. [[Crossref](#)]
25. Linda Y Tang, Jingping Wang (2020) Response to "Systematic Application of Rapid Sequence Intubation With Remifentanyl During COVID-19 Pandemic". *Semin Cardiothorac Vasc Anesth*. [[Crossref](#)]
26. Lin E, Choi J, Hadzic A (2013) Bloqueios nervosos periféricos para cirurgia ambulatorial: indicações baseadas em evidências. *Curr Opin Anaesthesiol* 26: 467.
27. Practice Recommendations on Neuraxial Anesthesia and Peripheral Nerve Blocks during the COVID-19 Pandemic.
28. COVID-19 Guidance for Regional Anesthesia Neuraxial Anesthesia and Peripheral Nerve Blocks. *Disponível em*.
29. Randy S Wax, Michael D Christian (2020) Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. *Can J Anesth* 67: 568-576. [[Crossref](#)]
30. Paw H, Shulman R (2014) Drugs in intensive care: an A-Z guide. 5th edition. *Cambridge: Cambridge University Press*.
31. Brull SJ, Meistelman C (2019) Pharmacology of Neuromuscular Blocking Drugs. *Miller's Anesthesia. Philadelphia: Elsevier* 792-831.
32. Pino RM, Ali HH (2018) Monitoring and Managing Neuromuscular Blockade. *Anesthesiology. New York: McGraw-Hill education* 444-461.
33. Stullitel A, Sousa AM (1998) Analgesia, sedação e bloqueio neuromuscular em UTI. *Medicina (Ribeirão Preto. Online)* 31: 507-516.
34. Bresolin NL, Fernandes VR. (2002) Sedação, analgesia e bloqueio neuromuscular. *AMIB-Associação de Medicina Intensiva Brasileira*.
35. Empresa Brasileira de Serviços Hospitalares (EBSERH). Protocolo Clínico COVID 19: Intubação Oro-traqueal UTI adultos. *Santa Catarina*.
36. Sang Hwan Do (2013) Magnesium: a versatile drug for anesthesiologists. *Korean J Anesthesiol* 65: 4-8. [[Crossref](#)]
37. A Higgs, B A McGrath, C Goddard, J Rangasami, G Suntharalinga (2018) Guidelines for the management of tracheal intubation in critically ill adults. *Br J Anaesth* 120: 323-352. [[Crossref](#)]
38. Lien CA, Eikermann M (2019) Neuromuscular blockers and reversal drugs. *Pharmacology and physiology for anesthesia. Philadelphia: Elsevier* 428-454.
39. Ross W (2016) Rapid Sequence Induction. *World Federation Soc Anaesthesiol*.
40. Caro DA, Bush S. (2008) Pretreatment agents. In: *Manual of Emergency Airway Management*, 3rd ed, *Lippincott Williams & Wilkins, Philadelphia*.
41. B H Rowe, J A Bretzlaff, C Bourdon, G W Bota, C A Camargo Jr (2000) Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. *Cochrane Database Syst Rev* CD001490. [[Crossref](#)]

42. Vuyk J, Sitsen E, Reekers M (2019) Intravenous anesthetics. Miller's Anesthesia. Philadelphia: Elsevier 638-679.
43. Ziad A Ali, Rif S El Mallakh (2020) Nebulized Lidocaine in COVID-19, An Hypothesis. *Med Hypotheses* 144: 109947. [[Crossref](#)]
44. Lauren K Dunn, Marcel E Durieux (2017) Perioperative use of intravenous lidocaine. *Anesthesiology* 126: 729-737. [[Crossref](#)]
45. Afonso J, Reis F (2012) Dexmedetomidina: Papel Atual em Anestesia e Cuidados Intensivos. *Revista Brasileira de Anestesiologia* 62.
46. Leal PC, Moura ECR, Falcão LFR (2016) Fármacos adjuvantes. Bases da anestesia venosa. *Rio de Janeiro* 95-103.
47. John Stockton, Cameron Kyle-Sidell (2020) Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A case report. *Am J Emerg Med*. [[Crossref](#)]
48. Dershwitz M, Rosow CE Intravenous anesthetics. *Anesthesiology*. New York: McGraw-Hill Education 636-650.
49. Susanne Herroeder, Marianne E Schönherr, Stefan G De Hert, Markus W Hollmann (2011) Magnesium-essentials for anesthesiologists. *Anesthesiology* 114: 971-993. [[Crossref](#)]
50. Susan Marland, John Ellerton, Gary Andolfatto, Giacomo Strapazzon, Oyvind Thomassen et al. (2013) Ketamine: use in anesthesia. *CNS Neurosci Ther* 19: 381-389. [[Crossref](#)]
51. Jessica A Darnobid (2015) The pharmacology of total intravenous anesthesia. *Int Anesthesiol Clin* 53: 13-27. [[Crossref](#)]
52. Gertrude J Nieuwenhuijs Moeke, Jayant S Jainandunsing, Michel M R F Struys (2020) Sevoflurane, a sigh of relief in COVID-19? *Br J Anaesth* 125: 118-121. [[Crossref](#)]
53. Flood P, Shafer S (2015) Inhaled Anesthetics. Pharmacology & physiology in anesthetic practice. Philadelphia: Wolters Kluwer 98-159.
54. Robert D Sanders, Jörg Weimann, Mervyn Maze (2008) Biologic effects of nitrous oxide a mechanistic and toxicologic review. *Anesthesiology* 109: 707-722. [[Crossref](#)]
55. White PF (2005) Perioperative drugs manual. 2nd ed. Philadelphia: Elsevier.
56. Nunes RR, Medeiros GP (2018) Princípios de física. Anestesiologia. Porto Alegre: Artmed 212-231.
57. Evgenov OV, Liang Y, Jiang Y (2019) Pulmonary pharmacology and inhaled anesthetics. Miller's Anesthesia. Philadelphia: Elsevier 638-679.
58. Hudson AE, Herold KF, Hemmings Jr HC (2019) Pharmacology of inhaled anesthetics. Pharmacology and physiology for anesthesia. Philadelphia: Elsevier 217-240.
59. Angela Jerath, Niall D Ferguson, Brian Cuthbertson (2020) Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS. *Intensive Care Med* 46: 1563-1566. [[Crossref](#)]
60. Philip L Hooper (2020) COVID-19 and heme oxygenase: novel insight into the disease and potential therapies. *Cell Stress Chaperones* 1-4. [[Crossref](#)]
61. Beverley A Orser, Dian Shi Wang, Wei Yang Lu (2020) Sedating ventilated COVID-19 patients with inhalational anesthetic drugs. *EBioMedicine* 55: 102770. [[Crossref](#)]